<DOC>
	<DOCNO>NCT00734474</DOCNO>
	<brief_summary>This adaptive dose find study Phase 3 efficacy study evaluate effect weekly injection LY2189265 compare Sitagliptin glucose measuring glycosylated hemoglobin ( HbA1c ) change baseline 52 week participant type 2 diabetes mellitus Metformin .</brief_summary>
	<brief_title>A Study LY2189265 Compared Sitagliptin Participants With Type 2 Diabetes Mellitus Metformin</brief_title>
	<detailed_description>This double blind study design select 1 2 LY2189265 dos evaluation Phase 3 study ( dose-finding portion ) evaluate efficacy safety select dos LY2189265 comparison Sitagliptin ( 100 milligram ) 104 week Placebo 26 week participant type 2 diabetes mellitus Metformin ( confirmatory , Phase 3 portion ) . The primary objective show non-inferiority high LY2189265 dose ( 2 dos select ) Sitagliptin respect change glycosylated hemoglobin ( HbA1c ) 52 week . The final endpoint 104 week . Participants randomize receive Placebo , Sitagliptin , 1 7 initial LY2189265 dos dose decision make base quantitative analysis benefit risk LY2189265 dose . A clinical utility index ( CUI ) applies predict value change baseline HbA1c 12 month change baseline weight , diastolic blood pressure , pulse rate 6 month LY2189265 dose use toward end . After dose decision , participant select LY2189265 arm comparator arm ( Sitagliptin Placebo/Sitagliptin arm ) continue study , additional participant randomize select comparator arm . Regardless time randomization relative dose decision point , participant select comparator arm plan receive treatment 104 week ; participant Placebo/Sitagliptin arm receive Placebo treatment 26 week follow Sitagliptin 100 mg 78 week blind purpose , participant select Sitagliptin arm receive treatment 104 week . All participant remain blinded study treatment throughout study . Participants non-selected arm discontinue study dose decision</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Diabetes mellitus , type 2 , least 6 month Treatment regimen : diet exercise , metformin monotherapy combination another oral antihyperglycemic medication ( OAM ) , another OAM monotherapy . Must able tolerate metformin dose least 1500 milligram ( mg ) daily 6 week prior randomization . Glycosylated hemoglobin ( HbA1c ) value ≥7.0 % ≤9.5 % , except participant diet exercise therapy must HbA1c value &gt; 8.0 % ≤9.5 % Body mass index ( BMI ) 25 40 kilogram per meter square ( kg/m^2 ) , inclusive Stable weight 3 month prior screen Females childbearing potential must test negative pregnancy agree use reliable birth control method Diabetes mellitus , type 1 Use glucagonlike peptide1 ( GLP1 ) analog ( example , exenatide ) within 6 month prior screen treat insulin Gastric empty abnormality , history bariatric surgery , chronic use drug affect gastrointestinal motility Use medication promote weight loss Clinicallyrelevant cardiovascular event within 6 month prior screen Poorly control hypertension Electrocardiogram ( ECG ) reading consider outside normal limit indicate cardiac disease Liver disease , hepatitis , chronic pancreatitis , idiopathic acute pancreatitis , alanine transaminase ( ALT ) level &gt; 3.0 time upper limit normal Serum creatinine ≥1.5 milligrams per deciliter ( mg/dL ) creatinine clearance &lt; 60 milliliter per minute ( mL/minute ) Uncontrolled diabetes , define &gt; 2 episode ketoacidosis hyperosmolar state require hospitalization 6 month prior study entry . Uncontrolled endocrine autoimmune abnormality History transplant organ Chronic use systemic glucocorticoid therapy Active untreated malignancy Use central nervous system ( CNS ) stimulant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Diabetes , type 2 diabetes</keyword>
</DOC>